- In U-EXCEL, the second of two Phase 3 induction studies, a significantly higher proportion of patients with moderate to severe Crohn's disease treated with upadacitinib (45 mg once daily for induction) achieved both primary endpoints of clinical remission[a,b] and endoscopic response[c], compared to placebo at week 12[1]
- In this study, upadacitinib also met most key secondary endpoints, consistent with findings from the first Phase 3 induction study, U-EXCEED[1]
- The study showed that a significantly higher proportion of upadacitinib-treated patients achieved steroid-free clinical remission[d] at week 12 compared to placebo[1]
- Safety results were consistent with the known profile of upadacitinib, with no new safety risks observed[1-6]
- Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral therapy for moderate to severe Crohn's disease and several other immune-mediated inflammatory diseases[1],[6-14]
PR Newswire
NORTH CHICAGO, Ill., Feb. 24, 2022
